ECONOMIC EVALUATION OF ANAFERON® IN THE TREATMENT OF ACUTE RESPIRATORY INFECTIONS IN MEXICO
Author(s)
Paladio-Hernández JÁ1, Pérez VM2
1UAM-Azcapotalco, Cuautitlán Izcalli, Mexico, 2BIOPHARMEX, Mexico City, Mexico
Presentation Documents
OBJECTIVES: Respiratory tract infections are one of the society’s main health problems due to the high rate of hospitalization, morbidity and mortality. Despite the overall impact on human health, there are relatively few therapeutic options available to prevent or treat respiratory infections. Children can present between six and eight respiratory infections per year, many of which, especially those occurring during the infant period, affect the lower respiratory tract. Anaferon® (affinity-purified antibody to interferon gamma) promotes an immunomodulatory and antiviral action. Its efficacy in relation to acute viral respiratory infections has been established clinically and experimentally. The objective of this study is to conduct a cost-effectiveness analysis of Anaferon® for the treatment of acute respiratory infections in children and adults compared with standard treatment. METHODS: This study used a decision tree, in which the costs and effectiveness of two treatment strategies in patients with acute respiratory infections (children or adult) were compared: Anaferon® plus standard care vs standard care (consultation plus treatment for the symptoms). The time horizon is six months.. RESULTS: Adding Anaferon® to the standard therapy is a cost-effective strategy over standard therapy, the incremental cost is $198 USD ($558 USD vs $360 USD). The administration of Anaferon® significantly reduced the duration of all the symptoms of the disease (4.68±0.08 vs 6.78±0.22 days). The duration in days of each symptom: fever (2.10±0.06 vs 3.37±0.19), intoxication (2.68±0.08 vs 4.63±0.19), cold symptoms (4.33±0.10 vs 6.79±0.23), gastrointestinal tract disorders (3.29±0.12 vs 4.65±0.26). For most of the children who received Anaferon® (81%) all the symptoms improved in 5 days vs 8 days for standard therapy alone. CONCLUSIONS: Anaferon® is a cost-effective alternative, it produces an immunomodulating effect, stimulates synthesis of IgA and IgG, exhibits cytoprotective activity, and improves local immunity of the upper airways in children and adults diagnosed with acute respiratory infections.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PRM136
Topic
Methodological & Statistical Research
Topic Subcategory
Modeling and simulation
Disease
Respiratory-Related Disorders